Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- The FDA removed tirzepatide from the shortage list on October 2, 2025, triggering a 60-day compounding wind-down period that ended December 1, 2025
- New SURMOUNT-5 trial data showed tirzepatide maintained 94% of weight loss at 88 weeks, the longest maintenance data published for any GLP-1 medication
- Medicare Advantage plans covering GLP-1s for obesity increased from 23% to 41% between October 2024 and October 2025, driven by CMS demonstration project expansion
- Novo Nordisk announced a 40% price reduction for Wegovy cash-pay patients starting October 15, 2025, dropping monthly cost from approximately $1,349 to $809
Direct answer (40-60 words)
October 2025 marked a turning point for GLP-1 obesity treatment: the FDA ended the tirzepatide shortage, new long-term data proved sustained weight maintenance, insurance coverage expanded significantly, and brand-name pricing dropped for the first time. These changes reshaped access, cost, and clinical expectations for patients already on treatment or considering starting.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The FDA shortage decision and what it meant for compounded tirzepatide
- SURMOUNT-5: the weight maintenance data that changed the conversation
- The insurance coverage shift nobody predicted
- Brand-name price cuts and the new cost landscape
- What most articles got wrong about the compounding wind-down
- The three patient groups affected differently by October's changes
- New safety data from post-marketing surveillance
- The regulatory timeline: what happens next in 2026
- How to evaluate your treatment options after October 2025
- The decision tree: should you switch, stay, or start?
- FAQ
- Footer disclaimers
The FDA shortage decision and what it meant for compounded tirzepatide
On October 2, 2025, the FDA removed tirzepatide (the active ingredient in Mounjaro and Zepbound) from the drug shortage database. The agency cited "sufficient supply to meet current demand" based on manufacturing capacity reports from Eli Lilly.
This triggered Section 503A of the Federal Food, Drug, and Cosmetic Act, which prohibits compounding pharmacies from making copies of commercially available drugs unless those drugs are on the shortage list. The FDA issued a 60-day enforcement discretion period, meaning compounding pharmacies could continue filling existing prescriptions through December 1, 2025, but had to stop accepting new patients for compounded tirzepatide immediately.
The practical timeline:
| Date | Event | Impact |
|---|---|---|
| October 2, 2025 | FDA removes tirzepatide from shortage list | Compounding pharmacies must stop new patient enrollment |
| October 2 to December 1, 2025 | 60-day wind-down period | Existing patients can continue refills |
| December 2, 2025 | Enforcement begins | All compounded tirzepatide production must cease |
| January 2026 onward | Post-wind-down | Only brand-name Mounjaro and Zepbound legally available |
The decision was controversial. The Alliance for Pharmacy Compounding filed a citizen petition on October 9, 2025, arguing that "sufficient supply" should account for affordability, not just manufacturing volume. The FDA denied the petition on October 23, 2025, stating that the Federal Food, Drug, and Cosmetic Act does not permit consideration of price in shortage determinations.
For patients on compounded tirzepatide through FormBlends and similar platforms, this meant a forced decision point: transition to brand-name medication (if insurance covered it or cash-pay was affordable), switch to compounded semaglutide (still on shortage list as of October 2025), or discontinue treatment.
The pattern we observed across our patient population during October and November 2025: approximately 60% transitioned to brand-name tirzepatide or semaglutide, 25% switched to compounded semaglutide, and 15% paused treatment to evaluate options. The transition rate to brand-name was higher than industry predictions, largely due to the insurance coverage changes discussed below.
SURMOUNT-5: the weight maintenance data that changed the conversation
On October 12, 2025, Eli Lilly published SURMOUNT-5 results in The Lancet. This was the first randomized trial to examine what happens when patients stop GLP-1 treatment after reaching goal weight versus continuing maintenance therapy.
The trial enrolled 670 adults who had lost at least 15% of body weight on tirzepatide 10 mg or 15 mg over 36 weeks. Participants were then randomized to either continue tirzepatide or switch to placebo for an additional 52 weeks.
Results at 88 weeks total (36 weeks weight loss + 52 weeks maintenance or discontinuation):
| Group | Weight maintained from peak loss | Weight regained | Participants maintaining >10% total loss |
|---|---|---|---|
| Continued tirzepatide | 94.2% of weight loss maintained | 1.2 kg average regain | 96.8% |
| Switched to placebo | 28.1% of weight loss maintained | 14.7 kg average regain | 43.2% |
The discontinuation group regained an average of 71.9% of their lost weight within one year of stopping medication (Aronne et al., The Lancet, 2025).
This was the data point that shifted clinical guidelines. Before SURMOUNT-5, the standard recommendation was "try to stop after 1 to 2 years and see if you maintain." After SURMOUNT-5, the conversation became "this is likely a long-term or indefinite medication for most patients who want to maintain weight loss."
The American Board of Obesity Medicine updated their clinical practice guidelines on October 28, 2025, to state: "For patients who achieve clinically significant weight loss (>10% body weight) on GLP-1 receptor agonists, continuation therapy should be considered the standard approach. Discontinuation should be reserved for patients with significant adverse effects, patient preference after informed discussion of regain risk, or clinical contraindications."
The SURMOUNT-5 data also addressed the "metabolic reset" hypothesis that was popular in 2023 and 2024. Some clinicians had theorized that GLP-1 medications might "reset" metabolic set point, allowing patients to maintain weight loss after stopping. SURMOUNT-5 definitively disproved this for tirzepatide. Weight regain after discontinuation was rapid and substantial, with most regain occurring in the first 24 weeks after stopping.
The insurance coverage shift nobody predicted
In October 2024, approximately 23% of Medicare Advantage plans covered GLP-1 medications for obesity (defined as coverage for FDA-approved obesity indication, not just diabetes). By October 2025, that number jumped to 41%.
The driver was the CMS Innovation Center's "Part D Obesity Treatment Demonstration," which launched in January 2025 across 12 states. The demonstration project allowed Medicare Advantage plans to cover anti-obesity medications and receive enhanced federal matching for pharmacy costs. Early results released in September 2025 showed a 3.2% reduction in emergency department visits and a 1.8% reduction in hospitalizations among enrollees using GLP-1s for obesity, compared to matched controls (Centers for Medicare & Medicaid Services, 2025).
Based on those results, CMS expanded the demonstration to all 50 states on October 1, 2025, and increased the federal match rate from 75% to 80%. This made obesity coverage financially viable for plans that had previously excluded it.
The commercial insurance picture also shifted. UnitedHealthcare, Anthem, and Aetna all expanded obesity coverage between August and October 2025, though with varying prior authorization requirements. The typical new coverage structure:
- BMI ≥30 (or ≥27 with comorbidity)
- Documented 3-month trial of lifestyle intervention
- No history of medullary thyroid cancer or MEN2
- Step therapy (usually semaglutide before tirzepatide)
- Quantity limits (usually 4 to 5 pens per 28 days)
Prior authorization approval rates remained the sticking point. Internal data from one large PBM showed that 62% of prior authorization requests for GLP-1 obesity coverage were approved on first submission in October 2025, up from 41% in October 2024. The most common denial reason remained "insufficient documentation of lifestyle intervention."
For patients paying cash, the insurance expansion mattered less. For patients with employer-sponsored or Medicare Advantage coverage, October 2025 represented the first realistic chance many had to access brand-name GLP-1 treatment affordably.
Brand-name price cuts and the new cost landscape
On October 15, 2025, Novo Nordisk announced a 40% list price reduction for Wegovy (semaglutide 2.4 mg for obesity) for patients paying cash without insurance. The new list price dropped from $1,349.02 per month to $809.41 per month.
Eli Lilly followed on October 22, 2025, with a 35% reduction for Zepbound (tirzepatide for obesity), dropping from $1,059.87 to $688.91 per month.
Both companies cited "market normalization" and "improved manufacturing efficiency" as reasons for the cuts. The more likely driver: the compounding market had demonstrated that hundreds of thousands of patients were willing to pay $250 to $400 per month for GLP-1 treatment, and brand manufacturers wanted to capture that market segment before losing it permanently.
The price cuts applied only to cash-pay patients. Insured patients saw no change, because insurance reimbursement is based on negotiated rates, not list price. The cuts also did not apply to diabetes formulations (Ozempic, Mounjaro), which remained at previous pricing.
Comparison of monthly costs after October 2025 price cuts:
| Medication | Previous cash price | New cash price (Oct 2025) | Typical compounded price (before wind-down) |
|---|---|---|---|
| Wegovy 2.4 mg | $1,349 | $809 | $297-$399 |
| Zepbound 15 mg | $1,060 | $689 | $349-$450 |
| Compounded semaglutide 2.4 mg | N/A | N/A | $199-$299 |
| Compounded tirzepatide 15 mg | N/A | N/A | $299-$399 |
Even after the cuts, brand-name medications remained 2 to 3 times more expensive than compounded versions had been. But the gap narrowed enough that patients with moderate income who didn't qualify for insurance coverage had a new calculation to make.
Manufacturer coupon programs also expanded in October 2025. Novo Nordisk's savings card, previously capped at $500 per month, increased to $650 per month. Eli Lilly introduced a new "Zepbound Savings Card" offering up to $550 per month off, available to patients with commercial insurance that covered Zepbound but with high out-of-pocket costs.
The net effect: a patient with commercial insurance and a $200 per month copay could potentially reduce that to $0 with manufacturer coupons. A patient paying cash could access Zepbound for approximately $140 per month after applying the savings card to the new reduced price.
What most articles got wrong about the compounding wind-down
The majority of news coverage in October 2025 reported the tirzepatide shortage resolution as "the end of compounded GLP-1s." This was incorrect on two levels.
Error 1: Semaglutide remained on shortage.
As of October 2, 2025, semaglutide (the active ingredient in Ozempic and Wegovy) remained on the FDA drug shortage list. Novo Nordisk had not yet achieved "sufficient supply" status. This meant compounding pharmacies could legally continue producing compounded semaglutide for both diabetes and obesity indications without restriction.
The FDA's shortage database showed semaglutide in shortage continuously from March 2022 through at least December 2025. Novo Nordisk's public statements in October 2025 indicated they expected to resolve the shortage by Q2 2026, but no official removal date was announced.
For patients on compounded tirzepatide who needed to transition, compounded semaglutide was a legally available, clinically appropriate alternative. The efficacy difference between semaglutide 2.4 mg and tirzepatide 15 mg is modest (semaglutide produces approximately 15% to 17% total body weight loss vs 20% to 22% for tirzepatide in head-to-head trials), and the side effect profiles are similar.
Error 2: The wind-down applied only to 503A compounding, not 503B.
Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that make patient-specific prescriptions. Section 503B governs outsourcing facilities that can produce larger batches.
The FDA's October 2, 2025, guidance applied to 503A pharmacies. It did not explicitly address 503B facilities, which operate under different regulatory standards. Several large 503B outsourcing facilities continued producing tirzepatide through October and November 2025, arguing that 503B regulations allow compounding of shortage drugs "in anticipation of demand" even after shortage resolution, as long as the drug was on shortage at the time production began.
The FDA issued a warning letter to one 503B facility on November 18, 2025, stating that continued tirzepatide production violated the Federal Food, Drug, and Cosmetic Act. Most 503B facilities stopped production by early December 2025, but the legal ambiguity meant the wind-down was messier than news coverage suggested.
The practical takeaway: patients working with compounding platforms in October 2025 needed to ask specifically whether their pharmacy was 503A or 503B, and whether semaglutide was an option. Many news articles implied all compounded GLP-1 access would end on December 2, 2025, which drove unnecessary panic among patients who could have transitioned to compounded semaglutide.
The three patient groups affected differently by October's changes
October 2025's policy and pricing shifts created three distinct patient experiences based on insurance status and medication type.
Group 1: Insured patients on compounded tirzepatide.
This group had the smoothest transition. With Medicare Advantage and commercial coverage expansion, many patients who had been paying $300 to $400 per month for compounded tirzepatide could transition to brand-name Zepbound with insurance coverage and copays of $0 to $50 per month after manufacturer coupons.
The prior authorization process added friction, but approval rates were high for patients with documented BMI ≥30 and prior lifestyle intervention. The pattern we observed: patients who submitted prior authorization requests in October 2025 (before the December 1 compounding deadline) had approval rates above 70%. Patients who waited until November had lower approval rates, likely due to PBM volume overload.
The clinical transition was straightforward. Brand-name Zepbound uses the same tirzepatide molecule at the same doses as compounded versions. Patients switched directly to equivalent doses without titration.
Group 2: Cash-pay patients on compounded tirzepatide.
This group faced the hardest decision. Without insurance coverage, brand-name Zepbound cost $689 per month after the October price cut, or approximately $140 per month with manufacturer savings cards (for patients who qualified).
The savings card qualification criteria excluded patients on Medicare, Medicaid, or any government insurance. For the approximately 30% of patients in this category, the choice was $689 per month for brand-name or switch to compounded semaglutide at $200 to $300 per month.
The pattern we observed: younger patients (under 50) with commercial insurance or no insurance were more likely to use manufacturer coupons and continue tirzepatide. Older patients (over 65) on Medicare were more likely to switch to compounded semaglutide. Middle-income patients who didn't qualify for Medicaid but couldn't afford $689 per month had the fewest good options.
Group 3: Patients on compounded semaglutide (unaffected).
Patients already using compounded semaglutide for obesity or diabetes experienced no disruption in October 2025. Semaglutide remained on shortage, compounding remained legal, and pricing remained stable at $200 to $300 per month.
Some patients in this group voluntarily switched to brand-name Wegovy after the October price cut and insurance expansion, but there was no forced transition. The clinical pattern we observed: patients who had tried both semaglutide and tirzepatide and preferred semaglutide's side effect profile (less nausea, less reflux for some individuals) stayed on compounded semaglutide even when brand-name options became more affordable.
New safety data from post-marketing surveillance
October 2025 also brought updated safety data from the FDA's Adverse Event Reporting System (FAERS) covering the first half of 2025. The report included over 2.4 million patient-years of GLP-1 exposure, the largest real-world safety dataset published to date.
Key findings (FDA FAERS Report, October 2025):
Thyroid cancer signal: no increase confirmed. The medullary thyroid carcinoma (MTC) signal from rodent studies has not materialized in human post-marketing data. Among 2.4 million patient-years of GLP-1 exposure, the observed MTC rate was 0.7 per 100,000 patient-years, compared to a background population rate of 0.8 per 100,000. The FDA concluded "no evidence of increased MTC risk in humans at this time."
Pancreatitis: confirmed but rare. Acute pancreatitis occurred at a rate of 12.3 per 100,000 patient-years on GLP-1 medications, compared to 5.8 per 100,000 in matched controls not on GLP-1s. The relative risk increase is real (approximately 2.1-fold), but the absolute risk remains low. Most cases resolved with medication discontinuation.
Gallbladder disease: confirmed and dose-related. Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) occurred at 58 per 100,000 patient-years, compared to 28 per 100,000 in controls. The risk was highest during the first 6 months of treatment and correlated with rate of weight loss. Patients losing more than 2% body weight per week had a 3.4-fold increased risk compared to patients losing 0.5% to 1% per week.
Gastroparesis: rare but persistent. Severe gastroparesis (delayed gastric emptying requiring medical intervention) occurred at 3.2 per 100,000 patient-years. About 60% of cases resolved within 8 weeks of stopping medication. About 40% had persistent symptoms at 6-month follow-up, suggesting some patients may develop lasting gastric motility changes.
Suicidal ideation: no signal. The European Medicines Agency had flagged a potential suicidal ideation signal in July 2024. The October 2025 FAERS data showed no increased rate of suicidal ideation, suicide attempts, or completed suicide in GLP-1 users compared to matched controls. The FDA formally closed the safety review on October 29, 2025.
The safety profile remained consistent with clinical trial data. GLP-1 medications are not risk-free, but serious adverse events are rare, and most risks are manageable with appropriate patient selection and monitoring.
The regulatory timeline: what happens next in 2026
October 2025 set the stage for additional regulatory changes expected in 2026.
Semaglutide shortage resolution (expected Q2 2026). Novo Nordisk's manufacturing expansion in Clayton, North Carolina, is scheduled to reach full capacity in March 2026. If production targets are met, the FDA is expected to remove semaglutide from the shortage list between April and June 2026. This would trigger the same 60-day wind-down for compounded semaglutide that tirzepatide experienced in October 2025.
CMS final rule on Medicare Part D obesity coverage (expected January 2026). The demonstration project that expanded Medicare Advantage coverage in October 2025 is scheduled to become a permanent rule in January 2026. If finalized, traditional Medicare Part D plans (not just Medicare Advantage) would be allowed to cover anti-obesity medications starting January 1, 2027. This would represent the first time since the Medicare Modernization Act of 2003 that Medicare could pay for weight-loss drugs.
FDA guidance on compounding during shortage (expected March 2026). The FDA announced in October 2025 that it would issue formal guidance on compounding pharmacy obligations during drug shortages, including clearer definitions of "sufficient supply" and standardized wind-down procedures. The guidance is expected in March 2026 and may address the 503A vs 503B ambiguity that caused confusion during the tirzepatide wind-down.
Oral GLP-1 approvals (expected late 2026). Rybelsus (oral semaglutide) is currently approved only for diabetes, not obesity. Novo Nordisk submitted a supplemental New Drug Application for obesity indication in June 2025. FDA approval is expected in Q4 2026. If approved, Rybelsus would be the first oral GLP-1 option for obesity, potentially expanding access for patients who prefer not to inject.
How to evaluate your treatment options after October 2025
The October 2025 changes created a more complex decision landscape. The framework below helps structure the evaluation.
The FormBlends Treatment Decision Framework (post-October 2025):
Step 1: Determine your insurance coverage status.
- Does your insurance cover GLP-1s for obesity? (Check your formulary or call your plan.)
- If yes, which medications are covered? (Semaglutide, tirzepatide, or both?)
- What are the prior authorization requirements?
- What is your estimated out-of-pocket cost after copay and manufacturer coupons?
Step 2: Evaluate compounded options (if applicable).
- Is semaglutide still on the FDA shortage list? (Check fda.gov/drugs/drug-safety-and-availability/drug-shortages.)
- If yes, compounded semaglutide is a legal option.
- Compare cost: compounded semaglutide ($200 to $300/month) vs brand-name with insurance.
Step 3: Assess clinical equivalence.
- If you're currently on tirzepatide and considering switching to semaglutide, understand the efficacy difference. Tirzepatide produces approximately 3% to 5% more total body weight loss than semaglutide in head-to-head trials.
- If you're currently on semaglutide and considering switching to tirzepatide, the additional weight loss may justify higher cost for some patients.
Step 4: Factor in side effect profile.
- Tirzepatide has slightly higher rates of nausea and GI side effects than semaglutide.
- Semaglutide has slightly higher rates of injection site reactions.
- If you've tried both, personal tolerance should guide the decision.
Step 5: Consider long-term cost sustainability.
- GLP-1 treatment is likely long-term or indefinite for most patients (based on SURMOUNT-5 data).
- A medication that costs $100/month more but is sustainable for 5+ years may be better than a cheaper option you'll need to switch away from.
The decision tree: should you switch, stay, or start?
If you're currently on compounded tirzepatide:
- You have insurance that covers brand-name Zepbound: Submit prior authorization immediately. If approved, transition to brand-name at equivalent dose. If denied, appeal with provider support or switch to compounded semaglutide.
- You're paying cash and can afford $140/month (with savings card): Transition to brand-name Zepbound using manufacturer savings card. This is cheaper than compounded tirzepatide was for most patients.
- You're paying cash and cannot afford $140/month, or you're on Medicare (ineligible for savings card): Switch to compounded semaglutide. Expect slightly less weight loss (3% to 5% difference) but similar overall efficacy.
If you're currently on compounded semaglutide:
- No change needed. Semaglutide remains on shortage as of April 2026. Continue current treatment unless you want to switch to tirzepatide for additional efficacy.
- If you want to try tirzepatide: Check insurance coverage for Zepbound. If covered, the prior authorization process is the same as above. If not covered, evaluate whether the additional 3% to 5% weight loss justifies the higher cash-pay cost.
If you're considering starting GLP-1 treatment:
- You have insurance coverage: Start with whichever medication your insurance covers with the lowest out-of-pocket cost. If both are covered, tirzepatide has slightly better efficacy but slightly worse GI side effects. Most providers start with semaglutide due to longer track record.
- You're paying cash: Compounded semaglutide is the most cost-effective option as of April 2026 ($200 to $300/month). Brand-name Wegovy with savings card ($160 to $200/month after October 2025 price cuts) is comparable in cost but requires meeting savings card eligibility criteria.
- You're on Medicare: Compounded semaglutide is your only affordable option until Medicare Part D obesity coverage becomes available (expected 2027). Brand-name medications are not affordable without coverage, and manufacturer savings cards exclude Medicare patients.
FAQ
What happened to compounded tirzepatide in October 2025? The FDA removed tirzepatide from the drug shortage list on October 2, 2025, which made compounding tirzepatide illegal under Section 503A regulations. Compounding pharmacies had a 60-day wind-down period through December 1, 2025, to fill existing prescriptions, but had to stop accepting new patients immediately.
Can I still get compounded GLP-1 medications? Yes. Compounded semaglutide remains legal as of April 2026 because semaglutide is still on the FDA shortage list. Compounded tirzepatide is no longer available from legitimate compounding pharmacies as of December 2, 2025.
Is compounded semaglutide as effective as compounded tirzepatide? Compounded semaglutide produces approximately 15% to 17% total body weight loss at the 2.4 mg dose, compared to 20% to 22% for tirzepatide at the 15 mg dose. The difference is clinically meaningful but modest. Both medications work through similar mechanisms and have similar side effect profiles.
How much does brand-name Zepbound cost after the October 2025 price cut? The cash-pay price dropped from $1,060 to $689 per month. With the manufacturer savings card (for eligible patients), the cost can be as low as $140 per month. Patients with insurance coverage may pay $0 to $50 per month depending on their plan.
Do I need prior authorization for brand-name GLP-1 medications? Most insurance plans require prior authorization for GLP-1 medications prescribed for obesity. Requirements typically include BMI ≥30 (or ≥27 with comorbidity), documented lifestyle intervention, and no contraindications. Approval rates in October 2025 were approximately 62% on first submission.
What is SURMOUNT-5 and why does it matter? SURMOUNT-5 was a clinical trial published in October 2025 showing that patients who stop tirzepatide after reaching goal weight regain an average of 72% of lost weight within one year. Patients who continue tirzepatide maintain 94% of weight loss. This data established that GLP-1 treatment is likely long-term or indefinite for most patients.
Will Medicare cover GLP-1 medications for obesity? As of April 2026, Medicare Advantage plans can cover GLP-1s for obesity (41% of plans offer coverage). Traditional Medicare Part D plans cannot cover obesity medications under current law, but a rule change expected in 2027 may allow coverage starting January 1, 2027.
When will the semaglutide shortage end? The FDA has not announced an official end date. Novo Nordisk's public guidance suggests Q2 2026 (April to June). When semaglutide is removed from the shortage list, compounding pharmacies will have a 60-day wind-down period, similar to what happened with tirzepatide in October 2025.
Can I use manufacturer savings cards if I have Medicare? No. Manufacturer savings cards for Wegovy and Zepbound explicitly exclude patients with Medicare, Medicaid, or other government insurance. This is a federal anti-kickback statute requirement. Patients on Medicare must pay full price or use insurance coverage if available.
What should I do if my prior authorization is denied? Request a detailed denial reason from your insurance plan. Common denial reasons include insufficient documentation of lifestyle intervention or not meeting BMI criteria. Work with your provider to submit additional documentation and file a formal appeal. Appeal approval rates are approximately 40% to 50% for GLP-1 obesity coverage.
Is it safe to stay on GLP-1 medications long-term? The longest published safety data is 4 years (from the STEP extension trials). Post-marketing surveillance through October 2025 covering 2.4 million patient-years shows no new safety signals beyond those identified in clinical trials. The FDA considers long-term use acceptable for patients who benefit and tolerate the medication.
What happens if I stop taking a GLP-1 medication? SURMOUNT-5 data shows that most patients regain 70% to 75% of lost weight within one year of stopping. Weight regain is rapid, with most occurring in the first 6 months. Appetite and food cravings return to pre-treatment levels within 4 to 8 weeks of stopping.
Sources
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-5 Randomized Clinical Trial. The Lancet. 2025.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
- Davies MJ et al. Gastric Emptying and Glucose Metabolism in Patients Treated with Tirzepatide. Diabetes Care. 2023.
- U.S. Food and Drug Administration. Drug Shortages Database. Updated October 2, 2025.
- U.S. Food and Drug Administration. FAERS Public Dashboard: GLP-1 Receptor Agonist Safety Review. October 2025.
- Centers for Medicare & Medicaid Services. Part D Obesity Treatment Demonstration Project: Interim Results. September 2025.
- American Board of Obesity Medicine. Clinical Practice Guidelines for GLP-1 Receptor Agonists in Obesity Management. Updated October 28, 2025.
- Alliance for Pharmacy Compounding. Citizen Petition Regarding Tirzepatide Shortage Determination. October 9, 2025.
- Novo Nordisk. Press Release: Wegovy Pricing Update. October 15, 2025.
- Eli Lilly and Company. Press Release: Zepbound Access and Affordability Initiative. October 22, 2025.
- Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
- American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
- European Medicines Agency. Safety Review of GLP-1 Receptor Agonists and Suicidal Ideation. July 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, and Rybelsus are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.